SCHEMBL678080

SCHEMBL678080

COc1ccc(-c2ccc(-c3ccc(C(=O)C(C)C)cc3)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.55
CES1 P23141 2/20 0.55
ALDH1A1 P00352 2/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
CYP1A2 P05177 1/20 0.54
CA1 P00915 5/20 0.53
CA2 P00918 5/20 0.53
PARP1 P09874 1/20 0.52
PARP10 Q53GL7 1/20 0.52
PARP2 Q9UGN5 1/20 0.52
PARP4 Q9UKK3 1/20 0.52
ESR2 Q92731 1/20 0.50
ALOX5 P09917 1/20 0.49
MAP4K4 O95819 1/20 0.49
RXRA P19793 1/20 0.49
PLK1 P53350 1/20 0.48
CYP3A4 P08684 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12453 0.94 CES2 (0.61) CES2CES1ALDH1A1RAB9ACYP1A2
SCHEMBL22548771 0.89 PARP10 (0.61) CES2CES1ALDH1A1RAB9ACYP1A2
SCHEMBL12418688 0.85 KDM4E (0.56) ALDH1A1RXRA
SCHEMBL18972860 0.82 CES2 (0.61) CES2CES1ALDH1A1NPC1RAB9A
SCHEMBL9405579 0.82 ALDH1A1 (0.49) CES2CES1ALDH1A1NPC1RAB9A
SCHEMBL9190993 0.82 ALDH1A1 (0.49) CES2CES1ALDH1A1NPC1RAB9A
SCHEMBL5217024 0.82 CES2 (0.61) CES2CES1ALDH1A1RAB9ACYP1A2
SCHEMBL24663641 0.81 RXFP1 (0.71) CES2CES1ALDH1A1NPC1RAB9A
SCHEMBL2633871 0.80 CES2 (0.59) CES2CES1ALDH1A1RAB9ACYP1A2
SCHEMBL22386732 0.80 SMN1; SMN2 (0.69) ALDH1A1NPC1RAB9APARP10RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902148-B2 Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent THERAVANCE, INC. (US) 2011-03-08 US disclosed
US-20090221470-A1 USE OF AN ECHINOCANDIN ANTIFUNGAL AGENT IN COMBINATION WITH A GLYCOPEPTIDE ANTIBACTERIAL AGENT CUMBERLAND PHARMACEUTICALS INC. 2009-09-03 US disclosed
US-7452861-B2 Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent THERAVANCE, INC. (US) 2008-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221470-A1 USE OF AN ECHINOCANDIN ANTIFUNGAL AGENT IN COMBINATION WITH A GLYCOPEPTIDE ANTIBACTERIAL AGENT DPM1, ERG28, ENGASE CES2 1770/4885CES1 2893/4885ALDH1A1 3363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.